Valuation: Rezolute, Inc.

Market Cap 431M 387M 357M 324M 606M 40.95B 613M 4.28B 1.7B 21.46B 1.62B 1.58B 68.07B P/E 2027 *
-5.82x
P/E 2028 * -7.95x
Enterprise Value 431M 387M 357M 324M 606M 40.95B 613M 4.28B 1.7B 21.46B 1.62B 1.58B 68.07B EV / Sales 2027 *
206x
EV / Sales 2028 * 7.97x
Free-Float
89.96%
Yield 2027 *
-
Yield 2028 * -

Last Transcript: Rezolute, Inc.

1 day+1.82%
1 week+13.38%
Current month+1.33%
1 month+0.36%
3 months-14.74%
6 months+36.64%
Current year+77.75%
1 week 3.67
Extreme 3.67
4.24
1 month 3.37
Extreme 3.37
4.91
Current year 1.87
Extreme 1.87
5.64
1 year 1.07
Extreme 1.07
11.46
3 years 0.72
Extreme 0.72
11.46
5 years 0.72
Extreme 0.72
11.46
10 years 0.72
Extreme 0.72
70
Manager TitleAgeSince
Chief Executive Officer 59 2013-01-29
Director of Finance/CFO 53 2024-01-22
Chief Operating Officer - -
Director TitleAgeSince
Chairman 59 2022-05-03
Director/Board Member 55 2019-11-19
Chairman 68 2019-02-09
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 Tax

Executive/Senior Manager

-2,267 0.0024%
7/2/26 Tax

Chief Technology Officer

-3,062 0.0035%
7/2/26 Tax

Chief Financial Officer

-3,062 0.0035%
Change 5-day change 1-year change 3-year change Capi.($)
+1.82%+13.38%-55.80%+299.52% 431M
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+1.27%+11.82%+82.12% 54.55B
-0.94%+0.99%+10.45%+102.18% 53.59B
+1.85%-0.22%+26.54%+55.80% 44.75B
+2.11%-3.28%+17.97%+100.31% 41.62B
+0.28%-3.90%+220.97%+917.49% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+47.63%+107.12%+94.27% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +4.07%+0.73%+40.86%+175.48% 38.09B
Weighted average by Cap. +3.00%-0.28%+46.92%+160.54%

Financials

2027 *2028 *
Net sales 2.09M 1.88M 1.74M 1.57M 2.94M 199M 2.98M 20.81M 8.27M 104M 7.86M 7.69M 331M 54.09M 48.55M 44.82M 40.65M 75.97M 5.14B 76.9M 537M 213M 2.69B 203M 199M 8.54B
Net income -79.49M -71.34M -65.87M -59.73M -112M -7.55B -113M -790M -314M -3.96B -298M -292M -12.55B -59.93M -53.79M -49.67M -45.04M -84.18M -5.69B -85.21M -595M -236M -2.98B -225M -220M -9.46B
Net Debt - -
Projected Income Statement - Annual - Rezolute, Inc.
Logo Rezolute, Inc.
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Employees
58
Date Price Change Volume
26-10-28 US$4.180 +1.70% 527,817
26-10-27 US$4.110 +7.59% 1,400,114
26-10-26 US$3.820 -0.91% 1,543,500
26-10-23 US$3.855 -0.13% 1,198,115
26-10-22 US$3.860 +4.32% 1,355,632
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Rezolute, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
4.110USD
Average target price
9.800USD
Spread / Average Target
+138.44%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Rezolute, Inc.
  1. Stock Market
  2. Stocks
  3. RZLT Stock